基于T细胞免疫的通用流感疫苗进展研究综述
Research Overview of Advances in Universal Influenza Vaccines Based on T-Cell Immunity
DOI: 10.12677/ACM.2023.1371594, PDF,   
作者: 林 颖：山东大学公共卫生学院，山东 济南
关键词: 流感病毒；通用疫苗；T细胞免疫；Influenza Virus； Universal Vaccine； T-Cell Immunity
摘要: 流行性感冒是一种广泛传播的呼吸道疾病，每年都会导致全球数百万人感染和数十万人死亡。目前的流感疫苗主要依赖于特定病毒株的识别，并且需要经常更新以适应流感病毒的变异。为了应对这一挑战，研究人员致力于开发一种通用流感疫苗，能够提供广谱的保护性免疫反应。本文综述了基于T细胞免疫的通用流感疫苗的最新进展研究。
Abstract: Influenza, also known as seasonal flu, is a widely spread respiratory disease that infects millions of people and causes hundreds of thousands of deaths worldwide each year. Current influenza vac-cines primarily rely on the recognition of specific viral strains and require regular updates to match the evolving influenza viruses. To address this challenge, researchers have been devoted to devel-oping a universal influenza vaccine that can provide broad-spectrum protective immune responses. This article provides an overview of the latest advances in research on universal influenza vaccines based on T-cell immunity.
文章引用：林颖. 基于T细胞免疫的通用流感疫苗进展研究综述[J]. 临床医学进展, 2023, 13(7): 11402-11408. https://doi.org/10.12677/ACM.2023.1371594

参考文献

[1] Krammer, F., Smith, G.J.D., Fouchier, R.A.M., Peiris, M., Kedzierska, K., Doherty, P.C., et al. (2018) Influenza. Nature Reviews Disease Primers, 4, Article No. 3. [Google Scholar] [CrossRef] [PubMed]
[2] Burnet, F.M. (1979) Portraits of Viruses: Influenza Virus A. Intervirology, 11, 201-214. [Google Scholar] [CrossRef] [PubMed]
[3] 李驰, 冯靖. 基于血凝素的新型流感疫苗的研究进展[J]. 中国生物制品学杂志, 2014, 27(2): 272-279.
[4] Gaitonde, D.Y., Moore, F.C. and Morgan, M.K. (2019) Influenza: Diagnosis and Treatment. American Family Physician, 100, 751-758.
[5] Taubenberger, J.K. and Morens, D.M. (2006) 1918 Influ-enza: The Mother of All Pandemics. Emerging Infectious Diseases, 12, 15-22. [Google Scholar] [CrossRef] [PubMed]
[6] Paget, J., Caini, S., Del Riccio, M., van Waarden, W. and Meijer, A. (2022) Has Influenza B/Yamagata Become Extinct and What Implications Might This Have for Quadrivalent Influenza Vaccines? Eurosurveillance, 27, Article ID: 2200753. [Google Scholar] [CrossRef] 
[7] Sederdahl, B.K. and Williams, J.V. (2020) Epi-demiology and Clinical Characteristics of Influenza C Virus. Viruses, 12, Article No. 89. [Google Scholar] [CrossRef] [PubMed]
[8] 中华预防医学会流感疫苗保护效果真实世界研究共识专家组. 流行性感冒疫苗保护效果真实世界研究专家共识[J]. 中国疫苗和免疫, 2022, 28(6): 617-637.
[9] Plotkin, J.B., Dush-off, J. and Levin, S.A. (2002) Hemagglutinin Sequence Clusters and the Antigenic Evolution of Influenza A Virus. Pro-ceedings of the National Academy of Sciences of the United States of America, 99, 6263-6268. [Google Scholar] [CrossRef] [PubMed]
[10] Smith, D.J., Lapedes, A.S., de Jong, J.C., Bestebroer, T.M., Rim-melzwaan, G.F., Osterhaus, A.D., et al. (2004) Mapping the Antigenic and Genetic Evolution of Influenza Virus. Science, 305, 371-376. [Google Scholar] [CrossRef] [PubMed]
[11] Sridhar, S., Begom, S., Bermingham, A., Hoschler, K., Adamson, W., Carman, W., et al. (2013) Cellular Immune Correlates of Protection against Symptomatic Pandemic Influenza. Nature Medicine, 19, 1305-1312. [Google Scholar] [CrossRef] [PubMed]
[12] Wang, Z., Wan, Y., Qiu, C., Quiñones-Parra, S., Zhu, Z., Loh, L., et al. (2015) Recovery from Severe H7N9 Disease Is Associated with Diverse Response Mechanisms Dominated by CD8⁺ T Cells. Nature Communications, 6, Article No. 6833. [Google Scholar] [CrossRef] [PubMed]
[13] Hayward, A.C., Wang, L., Goonetilleke, N., Fragaszy, E.B., Bermingham, A., Copas, A., et al. (2015) Natural T Cell-Mediated Protec-tion against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. American Journal of Respiratory and Critical Care Medicine, 191, 1422-1431. [Google Scholar] [CrossRef] 
[14] Valkenburg, S.A., Gras, S., Guillonneau, C., La Gruta, N.L., Thomas, P.G., Purcell, A.W., et al. (2010) Protective Efficacy of Cross-Reactive CD8+ T Cells Recognising Mutant Viral Epitopes Depends on Peptide-MHC-I Structural Interactions and T Cell Activation Threshold. PLOS Pathogens, 6, e1001039. [Google Scholar] [CrossRef] [PubMed]
[15] Grant, E.J., Josephs, T.M., Valkenburg, S.A., Wooldridge, L., Hellard, M., Rossjohn, J., et al. (2016) Lack of Heterologous Cross-Reactivity toward HLA-A*02:01 Restricted Viral Epitopes Is Underpinned by Distinct αβT Cell Receptor Signatures. Journal of Biological Chemistry, 291, 24335-24351. [Google Scholar] [CrossRef] 
[16] Quiñones-Parra, S.M., Clemens, E.B., Wang, Z., Croom, H.A., Kedzierski, L., McVernon, J., et al. (2016) A Role of Influenza Virus Exposure History in Determining Pandemic Sus-ceptibility and CD8+ T Cell Responses. Journal of Virology, 90, 6936-6947. [Google Scholar] [CrossRef] 
[17] Gerhard, W., Mozdzanowska, K. and Zharikova, D. (2006) Prospects for Universal Influenza Virus Vaccine. Emerging Infectious Diseases, 12, 569-574. [Google Scholar] [CrossRef] [PubMed]
[18] Grebe, K.M., Yewdell, J.W. and Bennink, J.R. (2008) Heterosubtypic Immunity to Influenza A Virus: Where Do We Stand? Microbes and Infection, 10, 1024-1029. [Google Scholar] [CrossRef] [PubMed]
[19] Koutsakos, M., Illing, P.T., Nguyen, T.H.O., Mifsud, N.A., Crawford, J.C., Rizzetto, S., et al. (2019) Human CD8+ T Cell Cross-Reactivity across Influenza A, B and C Viruses. Nature Immunology, 20, 613-625. [Google Scholar] [CrossRef] [PubMed]
[20] van de Sandt, C.E., Hillaire, M.L., Geelhoed-Mieras, M.M., Os-terhaus, A.D., Fouchier, R.A. and Rimmelzwaan, G.F. (2015) Human Influenza A Virus-Specific CD8+ T-Cell Re-sponse Is Long-Lived. The Journal of Infectious Diseases, 212, 81-85. [Google Scholar] [CrossRef] [PubMed]
[21] Rimmelzwaan, G.F., Fouchier, R.A. and Osterhaus, A.D. (2007) Influ-enza Virus-Specific Cytotoxic T Lymphocytes: A Correlate of Protection and a Basis for Vaccine Development. Current Opinion in Biotechnology, 18, 529-536. [Google Scholar] [CrossRef] [PubMed]
[22] Gras, S., Kedzierski, L., Valkenburg, S.A., Laurie, K., Liu, Y.C., Denholm, J.T., et al. (2010) Cross-Reactive CD8+ T-Cell Immunity between the Pandemic H1N1-2009 and H1N1-1918 Influenza A Viruses. Proceedings of the National Academy of Sciences of the United States of America, 107, 12599-12604. [Google Scholar] [CrossRef] [PubMed]
[23] Cruz, F.M., Colbert, J.D., Merino, E., Kriegsman, B.A. and Rock, K.L. (2017) The Biology and Underlying Mechanisms of Cross-Presentation of Exogenous Antigens on MHC-I Molecules. Annual Review of Immunology, 35, 149-176. [Google Scholar] [CrossRef] [PubMed]
[24] Trapani, J.A. and Smyth, M.J. (2002) Functional Significance of the Perforin/Granzyme Cell Death Pathway. Nature Reviews Immunology, 2, 735-747. [Google Scholar] [CrossRef] [PubMed]
[25] Price, G.E., Huang, L., Ou, R., Zhang, M. and Moskophidis, D. (2005) Per-forin and Fas Cytolytic Pathways Coordinately Shape the Selection and Diversity of CD8+-T-Cell Escape Variants of In-fluenza Virus. Journal of Virology, 79, 8545-8559. [Google Scholar] [CrossRef] 
[26] Laidlaw, B.J., Craft, J.E. and Kaech, S.M. (2016) The Multifaceted Role of CD4+ T Cells in CD8+ T Cell Memory. Nature Reviews Immunology, 16, 102-111. [Google Scholar] [CrossRef] [PubMed]
[27] Lopez, C.E. and Legge, K.L. (2020) Influenza A Virus Vaccination: Im-munity, Protection, and Recent Advances toward a Universal Vaccine. Vaccines (Basel), 8, Article No. 434. [Google Scholar] [CrossRef] [PubMed]
[28] Tarke, A., Coelho, C.H., Zhang, Z., Dan, J.M., Yu, E.D., Methot, N., et al. (2022) SARS-CoV-2 Vaccination Induces Immunological T Cell Memory Able to Cross-Recognize Variants from Alpha to Omicron. Cell, 185, 847-859.e11. [Google Scholar] [CrossRef] [PubMed]
[29] Weinfurter, J.T., Brunner, K., Capuano, S.V., Li, C., Broman, K.W., Kawaoka, Y., et al. (2011) Cross-Reactive T Cells Are Involved in Rapid Clearance of 2009 Pandemic H1N1 Influenza Virus in Nonhuman Primates. PLOS Pathogens, 7, e1002381. [Google Scholar] [CrossRef] [PubMed]
[30] Olukitibi, T.A., Ao, Z., Azizi, H., Mahmoudi, M., Coombs, K., Kobasa, D., et al. (2022) Development and Characterization of Influenza M2 Ectodomain and/or Hemagglutinin Stalk-Based Dendritic Cell-Targeting Vaccines. Frontiers in Microbiology, 13, Article ID: 937192. [Google Scholar] [CrossRef] [PubMed]
[31] Sette, A., Newman, M., Livingston, B., McKinney, D., Sidney, J., Ishioka, G., et al. (2002) Optimizing Vaccine Design for Cellular Processing, MHC Binding and TCR Recognition. Tis-sue Antigens, 59, 443-451. [Google Scholar] [CrossRef] [PubMed]
[32] Di Carluccio, A.R., Triffon, C.F. and Chen, W. (2018) Perpetual Complexity: Predicting Human CD8+ T-Cell Responses to Pathogenic Peptides. Immunology & Cell Biology, 96, 358-369. [Google Scholar] [CrossRef] [PubMed]
[33] Dönnes, P. and Elofsson, A. (2002) Prediction of MHC Class I Binding Peptides, Using SVMHC. BMC Bioinformatics, 3, Article No. 25. [Google Scholar] [CrossRef] [PubMed]
[34] Andreatta, M. and Nielsen, M. (2016) Gapped Sequence Alignment Using Artificial Neural Networks: Application to the MHC Class I System. Bioinformatics, 32, 511-517. [Google Scholar] [CrossRef] [PubMed]
[35] Vita, R., Mahajan, S., Overton, J.A., Dhanda, S.K., Martini, S., Cantrell, J.R., et al. (2019) The Immune Epitope Database (IEDB): 2018 Update. Nucleic Acids Research, 47, D339-D343. [Google Scholar] [CrossRef] [PubMed]
[36] 张磊, 严嘉玲, 马茜. 多肽疫苗研究进展[J]. 中国疫苗和免疫, 2023, 29(2): 231-238.
[37] Abbasi, J. (2021) Broad and Durable Antibody Response in Universal Flu Vaccine Trial. JAMA, 325, 121. [Google Scholar] [CrossRef] [PubMed]
[38] Oftung, F., Næss, L.M., Laake, I., Stoloff, G. and Pleguezuelos, O. (2022) FLU-v, a Broad-Spectrum Influenza Vaccine, Induces Cross-Reactive Cellular Immune Responses in Humans Measured by Dual IFN-γ and Granzyme B ELISpot Assay. Vaccines (Basel), 10, Article No. 1528. [Google Scholar] [CrossRef] [PubMed]
[39] Pleguezuelos, O., Dille, J., de Groen, S., Oftung, F., Niesters, H.G.M., Islam, M.A., et al. (2020) Immunogenicity, Safety, and Efficacy of a Standalone Universal Influenza Vaccine, FLU-v, in Healthy Adults: A Randomized Clinical Trial. Annals of Internal Medicine, 172, 453-462. [Google Scholar] [CrossRef] 
[40] 赵淑敏, 陈继军. 通用流感疫苗研究进展[J]. 微生物学免疫学进展, 2023, 51(2): 60-68.
[41] Francis, J.N., Bunce, C.J., Horlock, C., Watson, J.M., Warrington, S.J., Georges, B., et al. (2015) A Novel Peptide-Based Pan-Influenza A Vaccine: A Double Blind, Randomised Clinical Trial of Immunogenicity and Safety. Vaccine, 33, 396-402. [Google Scholar] [CrossRef] [PubMed]
[42] Atmar, R.L., Bernstein, D.I., Winokur, P., Frey, S.E., Angelo, L.S., Bryant, C., et al. (2023) Safety and Immunogenicity of Multimeric-001 (M-001) Followed by Seasonal Quadrivalent Inactivated Influenza Vaccine in Young Adults—A Randomized Clinical Trial. Vac-cine, 41, 2716-2722. [Google Scholar] [CrossRef] [PubMed]
[43] Atsmon, J., Caraco, Y., Ziv-Sefer, S., Shaikevich, D., Abramov, E., Volokhov, I., et al. (2014) Priming by a Novel Universal Influenza Vaccine (Multimer-ic-001)—A Gateway for Improving Immune Response in the Elderly Population. Vaccine, 32, 5816-5823. [Google Scholar] [CrossRef] [PubMed]
[44] Lowell, G.H., Ziv, S., Bruzil, S., Babecoff, R. and Ben-Yedidia, T. (2017) Back to the Future: Immunization with M-001 Prior to Trivalent Influenza Vaccine in 2011/12 Enhanced Pro-tective Immune Responses against 2014/15 Epidemic Strain. Vaccine, 35, 713-715. [Google Scholar] [CrossRef] [PubMed]
[45] Dorrell, L., Yang, H., Iversen, A.K., Conlon, C., Suttill, A., Lancaster, M., et al. (2005) Therapeutic Immunization of Highly Active Antiretroviral Therapy-Treated HIV-1-Infected Patients: Safety and Immunogenicity of an HIV-1 Gag/Poly-Epitope DNA Vaccine. Aids, 19, 1321-1323. [Google Scholar] [CrossRef] [PubMed]
[46] Berthoud, T.K., Hamill, M., Lillie, P.J., Hwenda, L., Collins, K.A., Ewer, K.J., et al. (2011) Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic In-fluenza A Vaccine, MVA-NP+M1. Clinical Infectious Diseases, 52, 1-7. [Google Scholar] [CrossRef] [PubMed]
[47] Evans, T.G., Bussey, L., Eagling-Vose, E., Rutkowski, K., Ellis, C., Argent, C., et al. (2022) Efficacy and Safety of a Universal Influenza A Vaccine (MVA-NP+M1) in Adults When Given after Seasonal Quadrivalent Influenza Vaccine Immunisation (FLU009): A Phase 2b, Randomised, Double-Blind Trial. The Lancet Infectious Diseases, 22, 857-866. [Google Scholar] [CrossRef] 
[48] Puksuriwong, S., Ahmed, M.S., Sharma, R., Krishnan, M., Leong, S., Lambe, T., et al. (2020) Modified Vaccinia Ankara-Vectored Vaccine Expressing Nucleoprotein and Matrix Protein 1 (M1) Activates Mucosal M1-Specific T-Cell Immunity and Tissue-Resident Memory T Cells in Human Naso-pharynx-Associated Lymphoid Tissue. The Journal of Infectious Diseases, 222, 807-819. [Google Scholar] [CrossRef] [PubMed]
[49] Guilfoyle, K., Major, D., Skeldon, S., James, H., Tingstedt, J.L., Polacek, C., et al. (2021) Protective Efficacy of a Polyvalent Influenza A DNA Vaccine against both Homologous (H1N1pdm09) and Heterologous (H5N1) Challenge in the Ferret Model. Vaccine, 39, 4903-4913. [Google Scholar] [CrossRef] [PubMed]

为你推荐